Amicus Therapeutics (FOLD) Downgraded by BidaskClub

BidaskClub cut shares of Amicus Therapeutics (NASDAQ:FOLD) from a buy rating to a hold rating in a research note issued to investors on Tuesday.

FOLD has been the topic of a number of other reports. Zacks Investment Research lowered shares of Amicus Therapeutics from a hold rating to a sell rating in a report on Tuesday, December 19th. Leerink Swann restated a buy rating and issued a $20.00 price objective (up from $17.00) on shares of Amicus Therapeutics in a report on Wednesday, October 4th. Robert W. Baird restated an outperform rating and issued a $16.00 price objective on shares of Amicus Therapeutics in a report on Monday, September 25th. Bank of America raised their price objective on shares of Amicus Therapeutics from $15.00 to $20.00 and gave the company a buy rating in a report on Wednesday, October 4th. Finally, Goldman Sachs Group restated a neutral rating and issued a $17.00 price objective on shares of Amicus Therapeutics in a report on Friday, October 6th. One research analyst has rated the stock with a sell rating, three have assigned a hold rating and six have assigned a buy rating to the stock. Amicus Therapeutics currently has an average rating of Buy and a consensus target price of $18.31.

Amicus Therapeutics (FOLD) traded down $0.15 during trading on Tuesday, reaching $15.72. 2,822,208 shares of the company’s stock were exchanged, compared to its average volume of 2,250,000. The firm has a market cap of $2,610.00, a price-to-earnings ratio of -8.59 and a beta of 1.72. Amicus Therapeutics has a 12 month low of $5.07 and a 12 month high of $16.60. The company has a debt-to-equity ratio of 0.39, a quick ratio of 6.22 and a current ratio of 6.32.

Amicus Therapeutics (NASDAQ:FOLD) last released its earnings results on Wednesday, November 8th. The biopharmaceutical company reported ($0.41) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.31) by ($0.10). Amicus Therapeutics had a negative return on equity of 63.54% and a negative net margin of 1,092.37%. The business had revenue of $10.90 million for the quarter, compared to analyst estimates of $9.02 million. During the same quarter last year, the company earned ($0.33) earnings per share. Amicus Therapeutics’s quarterly revenue was up 419.0% compared to the same quarter last year. analysts predict that Amicus Therapeutics will post -1.56 EPS for the current year.

In related news, insider Jay Barth sold 5,000 shares of Amicus Therapeutics stock in a transaction on Friday, December 1st. The shares were sold at an average price of $13.59, for a total transaction of $67,950.00. Following the sale, the insider now directly owns 69,184 shares in the company, valued at approximately $940,210.56. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, CEO John F. Crowley sold 449,295 shares of Amicus Therapeutics stock in a transaction on Monday, October 16th. The stock was sold at an average price of $14.33, for a total transaction of $6,438,397.35. Following the sale, the chief executive officer now owns 380,723 shares in the company, valued at $5,455,760.59. The disclosure for this sale can be found here. Insiders sold a total of 718,920 shares of company stock worth $10,263,669 over the last 90 days. Company insiders own 3.40% of the company’s stock.

A number of large investors have recently made changes to their positions in the stock. Sage Capital Advisors llc acquired a new stake in Amicus Therapeutics during the 3rd quarter worth $154,000. GSA Capital Partners LLP acquired a new stake in Amicus Therapeutics during the 3rd quarter worth $309,000. Iguana Healthcare Management LLC acquired a new stake in Amicus Therapeutics during the 3rd quarter worth $905,000. Sterling Capital Management LLC acquired a new stake in Amicus Therapeutics during the 3rd quarter worth $218,000. Finally, Neuberger Berman Group LLC acquired a new stake in Amicus Therapeutics during the 3rd quarter worth $196,000.

TRADEMARK VIOLATION NOTICE: This story was reported by Community Financial News and is the sole property of of Community Financial News. If you are viewing this story on another publication, it was stolen and reposted in violation of U.S. & international copyright & trademark laws. The correct version of this story can be viewed at https://www.com-unik.info/2018/01/13/amicus-therapeutics-fold-downgraded-by-bidaskclub.html.

Amicus Therapeutics Company Profile

Amicus Therapeutics, Inc is a biotechnology company. The Company is engaged in the discovery, development and commercialization of a set of treatments for patients living with devastating rare and orphan diseases. Its lead product, migalastat HCl is a small molecule that can be used as a monotherapy and in combination with enzyme replacement therapy (ERT) for Fabry disease.

Analyst Recommendations for Amicus Therapeutics (NASDAQ:FOLD)

Receive News & Ratings for Amicus Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amicus Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit